IMO 2125

Drug Profile

IMO 2125

Alternative Names: IMO-2125

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antivirals; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Preclinical Colorectal cancer; Lymphoma
  • Discontinued Hepatitis C

Most Recent Events

  • 17 Feb 2017 Idera Pharmaceuticals plans a phase I trial for Solid tumours (NCT03052205)
  • 28 Oct 2016 Idera Pharmaceuticals plans two clinical trials for Cancer (Monotherapy, Combination therapy) in USA
  • 26 Sep 2016 Initial safety and efficacy data from the phase I/II trial in Malignant melanoma was released by Idera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top